

# Biotech Financing Update

June 2018 – August 2018



UK BioIndustry Association



# Biotech Financing Update

## Overall figures


These figures capture the financing of UK-based biotechs from 1 June 2018 – 31 August 2018. As we moved into the second half of the year we saw an acceleration in venture capital fundraisings and an uplift in amounts raised in Initial Public Offering (IPO). Follow on financings remained steady in this period.

IPO	All other public financings	Venture Capital
<b>Q3 2018</b> <b>£191.67</b> <b>MILLION</b>	<b>Q3 2018</b> <b>£77.75</b> <b>MILLION</b>	<b>Q3 2018</b> <b>£462.6</b> <b>MILLION</b>
<b>Q2 2018</b> <b>£36</b> <b>MILLION</b>	<b>Q2 2018</b> <b>£64.85</b> <b>MILLION</b>	<b>Q2 2018</b> <b>£329.6</b> <b>MILLION</b>
<b>Q1 2018</b> <b>£0</b> <b>MILLION</b>	<b>Q1 2018</b> <b>£265.5</b> <b>MILLION</b>	<b>Q1 2018</b> <b>£134.9</b> <b>MILLION</b>
<b>TOTAL 2018</b> <b>to date</b> <b>£227.67 MILLION</b>	<b>TOTAL 2018</b> <b>to date</b> <b>£408.1 MILLION</b>	<b>TOTAL 2018</b> <b>to date</b> <b>£927.1 MILLION</b>
<b>TOTAL 2017</b> <b>£234 MILLION</b>	<b>TOTAL 2017</b> <b>£452 MILLION</b>	<b>TOTAL 2017</b> <b>£515 MILLION</b>

## Venture Capital Funding

Venture capital fundraising in the third quarter accelerated, with over £462 million raised, double the total for the first half of the year. Most of the activity was in A and B rounds but Orchard Therapeutics boosted C round takings with its large fundraise.

### UK VC Progression



### Top UK VC Rounds

Company Name	Round	£m
Orchard Therapeutics	C	114.5
Freeline Therapeutics	B	88
Artios Pharma	B	65
ReViral	A	41.98
Juvenesence	A	38.17
NodThera	A	28
KaNDY Therapeutics	C	25
Genomics plc	B	25
Blueberry Therapeutics	B	10
Endomagnetics	C	8

Source: Informa - Strategic Transactions and Scrip

## IPOs

Despite only two IPOs, UK biotechs have raised an impressive £191.67 million joining the public markets during this period.

BIA member Autolus achieved the first major IPO of 2018 for a UK biotech, banking £131.67 million on a buoyant Nasdaq. During the same period, 23 US companies completed IPOs raising over £1.7 billion.

In the UK, Sensyne Health achieved an impressive £60 million on AIM.



**£131.67m**

achieved by  
BIA member Autolus  
for first major IPO  
of 2018 for a UK biotech  
on a buoyant Nasdaq

# Biotech Financing Update

## Follow on financing

AIM has proved a valuable source of follow-on funding for UK biotechs during this period, providing over £77 million. However, GW Pharma's £221.6 million follow-on raise on Nasdaq at the beginning of the year continues to be a high point.



## Follow on financings

	Market	£m
Alliance Pharma	AIM	34
Angle plc	AIM	12
Avacta Group	AIM	11
Allergy Therapeutics	AIM	10.6
Oxford BioDynamics	AIM	9.75

## Follow on financing by market

	Q1	Q2	Q3
UK Main Market follow on	0	20.5	0
AIM follow on	43.9	44.35	77.75
Nasdaq follow on	221.6	0.0	0
Total	265.5	64.85	77.75

# Debt financing

Only one UK company has accessed debt financing in this round of data - Acacia Pharma. This type of financing remains relatively under-utilised by UK companies compared to the US and other countries.



Region	Debt* total £m	Count	Average £m
Massachusetts	227.27	2	113.635
Switzerland	158.73	1	158.73
Wisconsin	145.04	1	145.04
Texas	61.07	1	61.07
Florida	57.25	1	57.25
New York	38.17	1	38.17
France	26.7	3	8.9
San Diego	22.9	1	22.9
The Netherlands	17.86	1	17.86
Israel	10.71	2	5.355
UK	7.63	1	7.63

Source: Informa - Strategic Transactions and Scrip

[www.bioindustry.org](http://www.bioindustry.org) | [pharmaintelligence.informa.com](http://pharmaintelligence.informa.com)

# BIA Supporters



**horizon**  
INSPIRED CELL SOLUTIONS

*Johnson & Johnson*  
INNOVATION

**lifeArc**

**VWR**  
part of avacost

**Gallagher**  
Insurance | Risk Management | Consulting

**MedImmune**  
A member of the AstraZeneca Group

**BIA**  
UK BioIndustry Association